Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2025Frontiers in OncologyOpen Access

Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06)

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMeichen GuYGYuchen GuoLHLiang He

Discussion

Loading...

Member takes

Overview

Phase II trial explores pCR rates in high-risk rectal cancer, indicating potential for improved treatment outcomes.

Key Points

  • The study aims to improve the pCR rate in high-risk local advanced rectal cancer patients.
  • Primary endpoint is the pCR rate, with secondary measures including disease-free survival and safety outcomes.
  • This prospective trial combines long-course chemoradiotherapy with immunotherapy to assess effectiveness.
  • Exploration of this treatment approach may enhance outcomes for patients desiring anal sphincter preservation.

Cite This Study

Gu et al. (2025) studied this question.

synapsesocial.com/papers/68af2b68cf1dd9ea359e4cbchttps://doi.org/10.3389/fonc.2025.1594927
View Full Paper
Ask AI
Bookmark
Share